Leukemia Clinical Trials in New York

Showing 501-520 of 850 trials

Study of PTC299 (Emvododstat) in Relapsed/Refractory Acute Leukemias

NCT03761069

This is an open-label, non-randomized, Phase 1b study to evaluate the safety, pharmacokinetics (PK) profiles, and preliminary evidence of antitumor activity of PTC299 and the metabolite, O-desmethyl PTC299, in participants with relapsed/refractory acute myeloid leukemia (AML) who have exhausted standard available therapies known to provide clinical benefit. The study is designed as a series of cohort-based dose escalations. For each cohort, a minimum of 3 evaluable participants with PK and safety data will be assessed. Additional participants will be recruited if additional PK data are needed to assess mean exposure based on the observed variability.

Leukemia, Myeloid, AcuteAML

PTC Therapeutics33 participantsStarted Oct 2018

Aurora, Colorado, United States • New Haven, Connecticut, United States • Detroit, Michigan, United States +14 more locations

COMPLETEDPHASE3< 1 mile

Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes

NCT00369317

This phase III trial is studying how well combination chemotherapy works in treating young patients with Down syndrome and acute myeloid leukemia or myelodysplastic syndromes. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells.

Childhood Acute Basophilic LeukemiaChildhood Acute Eosinophilic LeukemiaChildhood Acute Erythroleukemia (M6)+12 more

Children's Oncology Group205 participantsStarted Mar 2007

Phoenix, Arizona, United States • Downey, California, United States • Long Beach, California, United States +94 more locations

Study of PTC299 (Emvododstat) in Relapsed/Refractory Acute Leukemias

Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes

Leukemia Trials in Other Cities

A Study of Idasanutlin With Cytarabine Versus Cytarabine Plus Placebo in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)

A Study of Venetoclax in Combination With Cobimetinib and Venetoclax in Combination With Idasanutlin in Patients With Relapsed or Refractory Acute Myeloid Leukemia Who Are Not Eligible for Cytotoxic Therapy

A Phase 1 Study of Nivolumab (BMS-936558) in Subjects With Advanced or Recurrent Malignancies

Evaluating Immune Therapy, Durvalumab (MEDI4736) With Tremelimumab for Metastatic, Non-transitional Cell Carcinoma of the Urinary Tract

Double Cord Versus Haploidentical (BMT CTN 1101)

Comprehensive Patient Questionnaires in Predicting Complications in Older Patients With Gynecologic Cancer Undergoing Surgery

Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children

Safety of and Immune Response to the Human Papillomavirus (HPV) Vaccine in HIV-Infected Women

Acute Myeloid Leukemia T Cell Depletion to Improve Transplants in Adults With Acute Myeloid Leukemia (BMT CTN 0303)

Study of AMV564 in Patients With AML

Drug Challenges Without Prior Skin Testing

Homoharringtonine (Omacetaxine Mepesuccinate) in Treating Patients With Chronic Myeloid Leukemia (CML) With the T315I BCR-ABL Gene Mutation

A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies

AR101 Real-World Open-Label Extension Study

Long Term Safety and Efficacy Trial of Beclomethasone Dipropionate - Hydrofluoroalkane (BDP-HFA) 320 mcg in Allergic Rhinitis

Safety Study of MGA271 in Refractory Cancer

Study of UCART19 in Pediatric Patients With Relapsed/Refractory B Acute Lymphoblastic Leukemia

Preoperative Chemotherapy and Bevacizumab in Patients With Stage IB (>4 cm), II, or Select Stage III NSCLC

Other Conditions in New York